Eli Lilly exceeded second-quarter earnings expectations, driven by strong sales of its weight-loss and diabetes drugs, Mounjaro and Zepbound. Revenue reached $15.56 billion, surpassing forecasts. The company raised its 2025 sales guidance to $60-$62 billion, reflecting strong growth. While late-stage trial data for its obesity pill, orforglipron, fell short of expectations, causing a temporary stock dip, CEO David Ricks expressed optimism about the company's future. The results come amidst potential tariffs on imported pharmaceuticals.

Prepared by Christopher Adams and reviewed by editorial team.